Apalutamide and Darolutamide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong or moderate CYP3A induction can reduce darolutamide exposure.
Clinical significance and safety
Apalutamide with Darolutamide can reduce darolutamide exposure and its treatment effect. The EMA product information does not recommend combining darolutamide with strong or moderate CYP3A4/P-gp inducers unless there is no therapeutic alternative. The oncology team should consider an option with less inducing potential and assess cancer-treatment effectiveness.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.